The Highland Capital Management Korea Limited is an affiliate of the mighty Highland Capital Management L.P, just recently started a 147M health care fund. The anchor investor for this fund was the National Pension Service of South Korea (NPS). The NPS was established in 1988, and to date, it is estimated to be value a staggering cost of KRW 565 which is an equivalent of $499.8billion. According to a different report by the Wealth Fund Institute, this body worth $ 465.13 billion.
Several other participants were working alongside the NPS Korea in raising the Highland funds. It is thought that they had their specific aims within the healthcare sector, and not concerned with investment returns. Their paramount objectives were to gain access to a myriad of investment opportunities to meet their strategic objectives strategic objectives in Korea, China, and the USA.
The Highland company is set to work with Korean Private Equity, and Venture Company dabbed Stone bridge Capital around Asia. This company will be in charge of managing the funds here. The venture in Asia is seen as the first ever private oriented health equity fund by the Highland Capital Management. This is however not to mean that Asian investors have no interest in health investment, but initially, their investments over the last two years have been on either direct basis or through multi-purpose funds.
Carl Moore is Highland’s managing director cum Co-head of Highland’s Private Equity Group. He explained that the fund’s strategy is in line with the company’s core capabilities, drawing on the company’s deep expertise in the healthcare field. He added that the field is his business’s largest industry exposure and that the company has roughly 15 years’ experience in private equity, throughout this time, they have focused on health care.
The fund’s primary target is the middle market companies throughout North America and Asia. Highland reported that over $1.5 billion was already in assets under management (AUM) as of May 2017. The Highland’s Capital Management, Private Equity Co-Head Mr. Watt Jameson revealed that the healthcare industry in the US was facing some disruptive forces which acutely affect enterprises in the middle market.